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Pre-eclampsia is a disease whose characterisa-tion has not changed since the cluster of
signs associated with the disorder were first
described 150 years ago. In Professor Murthi’s
own words from a recent publication in 2020,
she states: ‘It is hypothesized that the patho-
physiology of early-onset pre-eclampsia has its
origins in the placental and uterine vasculature,
where inadequate vascular remodelling leads to
repeated ischemic-reperfusion events within
placental tissue’ (Ellery et al. Int J Mol Sci.
2020;21:806). When even a placental biologist
seems unsure of the aetiology of this placental
disorder, it comes as no surprise that pre-
eclampsia has earned the moniker ‘disease of
theories’. Such theories predominate because
researchers have failed to provide biological
mechanisms relating the clinical epidemiology of
pre-eclampsia to observed cellular and organ
dysfunction.
All the evidence cited to support the placenta’s
role in pre-eclampsia is not in question – it is
self-evident to most clinicians and academics
that the placenta is central in the pathophysiol-
ogy of pre-eclampsia. However, the putative
aetiological role for the placenta in pre-eclamp-
sia is questionable when one considers that
both villous and vascular histological placental
lesions are neither sensitive or specific for pre-
eclampsia, with the overall prevalence of these
lesions being higher in placentae from uncom-
plicated than pre-eclamptic gestations (Falco
et al. Ultrasound Obstet Gynecol. 2017;50:295–
301). Surely, a re-evaluation of the evidence is
required for a condition that still claims the lives
of approximately 60 000 women each year
worldwide. An emerging alternative hypothesis
is that poor trophoblast development and pla-
cental dysfunction may result from maternal
cardiovascular dysfunction rather than the other
way around (www.youtube.com/watch?v=9_
wszfCNqqM) (B. Thilaganathan. Accessed 7
September 2020; open access).
Pre-eclampsia and cardiovascular disease share
similar risk factors (age, obesity, diabetes,
chronic kidney disease) and pre-existing cardio-
vascular disease is the strongest risk factor
(chronic hypertension, congenital heart disease)
for the development of pre-eclampsia. There is
now abundant evidence from peripheral wave-
form analysis (uterine, radial and ophthalmic
artery Doppler), maternal echocardiography
and angiogenic marker studies that maternal
cardiovascular dysfunction precedes the devel-
opment of pre-eclampsia by several weeks to
months. Importantly, cardiovascular signs and
symptoms predominate (hypertension, cerebral
oedema, stroke) in pre-eclampsia and persist in
the postpartum period where the legacy is a
chronic hypertension rate of 30% in the decade
following birth (Thilaganathan. Hypertension
2020;76:321–2; Thilaganathan et al. Hyperten-
sion 2019;73:522–31). Given these findings, it is
no surprise that most pre-eclampsia prevention
strategies employ cardiovascular drugs (aspirin,
calcium, statins, metformin and antihyperten-
sives).
Placenta malperfusion caused either by subopti-
mal maternal cardiovascular performance or as
a result of excessive pregnancy demand may
lead to pre-eclampsia following exactly the
same translational mechanisms previously
described. Despite the seriousness of the
maternal and fetal consequences of pre-eclamp-
sia, we have still to develop effective screening,
a reliable diagnostic test, effective therapy or
amelioration of the postpartum maternal car-
diovascular legacy. These will only become
available when academics and clinicians shed
the veneer of confirmation bias and accept the
strong arguments for the cardiovascular aetiol-
ogy of pre-eclampsia.
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